NewsBenzingaAC免疫公司宣布VACSYn第一阶段ACI-7104在早期帕金森病患者中100周的安全性和免疫原性结果：所有主要终点符合，一般安全且耐受性良好；强免疫原性表现，三次免疫后100%响应率 AC免疫公司宣布VACSYn第一阶段ACI-7104在早期帕金森病患者中100周的安全性和免疫原性结果：所有主要终点符合，一般安全且耐受性良好；强免疫原性表现，三次免疫后100%响应率 Benzinga 2026.09.23 11:05 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $42 Eos Energy Enterprises Now Expects FY26 Revenue In Lower Half Of Its $300M To $350M Range CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings Mizuho Maintains Outperform on Equifax, Lowers Price Target to $185 NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings
NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
